{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:28:25Z","timestamp":1789720105645,"version":"4.0.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007553","name":"Aids Fonds","doi-asserted-by":"publisher","award":["2011020"],"award-info":[{"award-number":["2011020"]}],"id":[{"id":"10.13039\/100007553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001117","name":"amfAR, The Foundation for AIDS Research","doi-asserted-by":"publisher","award":["1110680\u201377-RPRL"],"award-info":[{"award-number":["1110680\u201377-RPRL"]}],"id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["KICH2.V4P.AF23.001"],"award-info":[{"award-number":["KICH2.V4P.AF23.001"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Initiation of antiretroviral therapy (ART) during primary HIV-1 infection (PHI) has been proposed to limit the formation of HIV-1 reservoirs. However, it remains unknown whether temporary ART initiated during PHI has a long-term effect on viral persistence. Here, we longitudinally quantify HIV-1 persistence markers and immunological parameters in the participants (<jats:italic>n<\/jats:italic>\u2009=\u200964) of a randomized controlled trial comparing 24 or 60 weeks of temporary ART vs. no treatment during PHI, who subsequently (re)initiated ART during chronic HIV-1 infection (CHI) after a median period of 116 weeks without treatment (ISRCTN59497461). Levels of several HIV-1 persistence markers (cell-associated unspliced RNA, total DNA, and intact DNA) do not significantly differ and strongly positively correlate between early and CHI ART periods in the same participants. Early ART is associated with lower HIV-1 proviral sequence diversity and superior restoration of the CD4\/CD8 ratio, as well as lower levels of monocyte activation markers, compared to CHI ART, in the same participants. At CHI ART, intact HIV-1 DNA negatively correlates with HIV-specific T-cell responses. Finally, levels of HIV-1 persistence markers during CHI ART are lower in participants who had been pre-treated during PHI, indicating a long-term suppressive effect of temporary early ART on the persistence of HIV-1 reservoir.<\/jats:p>","DOI":"10.1038\/s41467-025-62362-0","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:28:03Z","timestamp":1753889283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistence"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-4251","authenticated-orcid":false,"given":"Alexander O.","family":"Pasternak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pien M.","family":"van Paassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7217-1460","authenticated-orcid":false,"given":"Yara L.","family":"Verschoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelmer","family":"Vroom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel A.","family":"van Dort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-7313","authenticated-orcid":false,"given":"Marlous L.","family":"Grijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-8115","authenticated-orcid":false,"given":"Ferdinand W.","family":"Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-9570","authenticated-orcid":false,"given":"Godelieve J.","family":"de Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-7754","authenticated-orcid":false,"given":"Neeltje A.","family":"Kootstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1905-8486","authenticated-orcid":false,"given":"Ben","family":"Berkhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"62362_CR1","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat. Med. 27, 2085\u20132098 (2021).","journal-title":"Nat. Med."},{"key":"62362_CR2","doi-asserted-by":"publisher","first-page":"101301","DOI":"10.1016\/j.coviro.2023.101301","volume":"59","author":"AO Pasternak","year":"2023","unstructured":"Pasternak, A. O. & Berkhout, B. HIV persistence: silence or resistance?. Curr. Opin. Virol. 59, 101301 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"62362_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.3389\/fimmu.2019.02251","volume":"10","author":"G Darcis","year":"2019","unstructured":"Darcis, G., Berkhout, B. & Pasternak, A. O. The quest for cellular markers of HIV reservoirs: any color you like. Front. Immunol. 10, 2251 (2019).","journal-title":"Front. Immunol."},{"key":"62362_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","volume":"24","author":"DJ Colby","year":"2018","unstructured":"Colby, D. J. et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med, 24, 923\u2013926 (2018).","journal-title":"Nat. Med,"},{"key":"62362_CR5","doi-asserted-by":"publisher","first-page":"e1002417","DOI":"10.1371\/journal.pmed.1002417","volume":"14","author":"TJ Henrich","year":"2017","unstructured":"Henrich, T. J. et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med. 14, e1002417 (2017).","journal-title":"PLoS Med."},{"key":"62362_CR6","doi-asserted-by":"publisher","first-page":"10056","DOI":"10.1128\/JVI.01046-14","volume":"88","author":"MJ Buzon","year":"2014","unstructured":"Buzon, M. J. et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J. Virol. 88, 10056\u201310065 (2014).","journal-title":"J. Virol."},{"key":"62362_CR7","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/infdis\/jit311","volume":"208","author":"V Jain","year":"2013","unstructured":"Jain, V. et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J. Infect. Dis. 208, 1202\u20131211 (2013).","journal-title":"J. Infect. Dis."},{"key":"62362_CR8","doi-asserted-by":"publisher","first-page":"e13310","DOI":"10.1371\/journal.pone.0013310","volume":"5","author":"A Schmid","year":"2010","unstructured":"Schmid, A. et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS ONE 5, e13310 (2010).","journal-title":"PLoS ONE"},{"key":"62362_CR9","doi-asserted-by":"publisher","first-page":"e09115","DOI":"10.7554\/eLife.09115","volume":"4","author":"E Malatinkova","year":"2015","unstructured":"Malatinkova, E. et al. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. Elife 4, e09115 (2015).","journal-title":"Elife"},{"key":"62362_CR10","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1016\/S2666-5247(21)00010-0","volume":"2","author":"M Massanella","year":"2021","unstructured":"Massanella, M. et al. Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet Microbe 2, e198\u2013e209 (2021).","journal-title":"Lancet Microbe"},{"key":"62362_CR11","doi-asserted-by":"crossref","unstructured":"Leyre L. et al. Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. Sci. Transl. Med. 12, eaav3491 (2020).","DOI":"10.1126\/scitranslmed.aav3491"},{"key":"62362_CR12","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1086\/428777","volume":"191","author":"MC Strain","year":"2005","unstructured":"Strain, M. C. et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191, 1410\u20131418 (2005).","journal-title":"J. Infect. Dis."},{"key":"62362_CR13","doi-asserted-by":"crossref","unstructured":"Yerly S. et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. ADS. 14, 243\u2013249 (2000).","DOI":"10.1097\/00002030-200002180-00006"},{"key":"62362_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/00002030-200104130-00001","volume":"15","author":"N Ngo-Giang-Huong","year":"2001","unstructured":"Ngo-Giang-Huong, N. et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 15, 665\u2013673 (2001).","journal-title":"AIDS"},{"key":"62362_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/QAD.0000000000000625","volume":"29","author":"WJ Hey-Cunningham","year":"2015","unstructured":"Hey-Cunningham, W. J. et al. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. AIDS 29, 911\u2013919 (2015).","journal-title":"AIDS"},{"key":"62362_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/infdis\/jiu827","volume":"212","author":"GU van Zyl","year":"2015","unstructured":"van Zyl, G. U. et al. Early antiretroviral therapy in South African children reduces HIV-1-infected cells and cell-associated HIV-1 RNA in blood mononuclear cells. J. Infect. Dis. 212, 39\u201343 (2015).","journal-title":"J. Infect. Dis."},{"key":"62362_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature14053","volume":"517","author":"K Deng","year":"2015","unstructured":"Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381\u2013385 (2015).","journal-title":"Nature"},{"key":"62362_CR18","doi-asserted-by":"publisher","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013","unstructured":"S\u00e1ez-Ciri\u00f3n, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).","journal-title":"PLoS Pathog."},{"key":"62362_CR19","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","volume":"218","author":"G Namazi","year":"2018","unstructured":"Namazi, G. et al. The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J. Infect. Dis. 218, 1954\u20131963 (2018).","journal-title":"J. Infect. Dis."},{"key":"62362_CR20","doi-asserted-by":"publisher","first-page":"e1001196","DOI":"10.1371\/journal.pmed.1001196","volume":"9","author":"ML Grijsen","year":"2012","unstructured":"Grijsen, M. L. et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 9, e1001196 (2012).","journal-title":"PLoS Med."},{"key":"62362_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1110039","volume":"368","author":"S Fidler","year":"2013","unstructured":"Fidler, S. et al. Short-course antiretroviral therapy in primary HIV infection. N. Engl. J. Med. 368, 207\u2013217 (2013).","journal-title":"N. Engl. J. Med."},{"key":"62362_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/aid.2009.0041","volume":"26","author":"R Steingrover","year":"2010","unstructured":"Steingrover, R. et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res. Hum. Retroviruses 26, 379\u2013387 (2010).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"62362_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/QAD.0b013e328305bd77","volume":"22","author":"R Steingrover","year":"2008","unstructured":"Steingrover, R. et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 22, 1583\u20131588 (2008).","journal-title":"AIDS"},{"key":"62362_CR24","doi-asserted-by":"publisher","first-page":"e43754","DOI":"10.1371\/journal.pone.0043754","volume":"7","author":"E Hamlyn","year":"2012","unstructured":"Hamlyn, E. et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS ONE 7, e43754 (2012).","journal-title":"PLoS ONE"},{"key":"62362_CR25","doi-asserted-by":"publisher","first-page":"e27463","DOI":"10.1371\/journal.pone.0027463","volume":"6","author":"V Wyl","year":"2011","unstructured":"Wyl, V. et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE 6, e27463 (2011).","journal-title":"PLoS ONE"},{"key":"62362_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1086\/506616","volume":"194","author":"FM Hecht","year":"2006","unstructured":"Hecht, F. M. et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194, 725\u2013733 (2006).","journal-title":"J. Infect. Dis."},{"key":"62362_CR27","doi-asserted-by":"crossref","unstructured":"Pasternak A. O. et al. Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. JCI Insight. 5, e134196 (2020).","DOI":"10.1172\/jci.insight.134196"},{"key":"62362_CR28","doi-asserted-by":"crossref","unstructured":"Scherpenisse M., Kootstra N. A., Bakker M., Berkhout B., Pasternak A. O. Cell-associated HIV-1 unspliced-to-multiply-spliced RNA ratio at 12 weeks of ART predicts immune reconstitution on therapy. mBio. 12, e00099-21 (2021).","DOI":"10.1128\/mBio.00099-21"},{"key":"62362_CR29","doi-asserted-by":"publisher","first-page":"e8490","DOI":"10.1371\/journal.pone.0008490","volume":"4","author":"AO Pasternak","year":"2009","unstructured":"Pasternak, A. O. et al. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS ONE 4, e8490 (2009).","journal-title":"PLoS ONE"},{"key":"62362_CR30","doi-asserted-by":"crossref","unstructured":"Peluso M. J. et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. JCI Insight. 5, e132997 (2020)","DOI":"10.1172\/jci.insight.132997"},{"key":"62362_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08431-7","volume":"10","author":"MR Pinzone","year":"2019","unstructured":"Pinzone, M. R. et al. Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nat. Commun. 10, 728 (2019).","journal-title":"Nat. Commun."},{"key":"62362_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/infdis\/jiaa532","volume":"223","author":"RT Gandhi","year":"2021","unstructured":"Gandhi, R. T. et al. Selective decay of intact HIV-1 proviral DNA on antiretroviral therapy. J. Infect. Dis. 223, 225\u2013233 (2021).","journal-title":"J. Infect. Dis."},{"key":"62362_CR33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/infdis\/jis502","volume":"206","author":"AO Pasternak","year":"2012","unstructured":"Pasternak, A. O. et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J. Infect. Dis. 206, 1443\u20131452 (2012).","journal-title":"J. Infect. Dis."},{"key":"62362_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/QAD.0000000000000974","volume":"30","author":"S Leth","year":"2016","unstructured":"Leth, S. et al. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. AIDS 30, 713\u2013721 (2016).","journal-title":"AIDS"},{"key":"62362_CR35","doi-asserted-by":"publisher","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","volume":"10","author":"S Serrano-Villar","year":"2014","unstructured":"Serrano-Villar, S. et al. HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 10, e1004078 (2014).","journal-title":"PLoS Pathog."},{"key":"62362_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-018-0200-4","volume":"15","author":"WM Han","year":"2018","unstructured":"Han, W. M. et al. CD4\/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV. AIDS Res. Ther. 15, 13 (2018).","journal-title":"AIDS Res. Ther."},{"key":"62362_CR37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","volume":"43","author":"S Palmer","year":"2005","unstructured":"Palmer, S. et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43, 406\u2013413 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"62362_CR38","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1128\/JVI.02139-15","volume":"90","author":"MF Kearney","year":"2015","unstructured":"Kearney, M. F. et al. Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy. J. Virol. 90, 1369\u20131376 (2015).","journal-title":"J. Virol."},{"key":"62362_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrg1246","volume":"5","author":"A Rambaut","year":"2004","unstructured":"Rambaut, A., Posada, D., Crandall, K. A. & Holmes, E. C. The causes and consequences of HIV evolution. Nat. Rev. Genet. 5, 52\u201361 (2004).","journal-title":"Nat. Rev. Genet."},{"key":"62362_CR40","doi-asserted-by":"crossref","unstructured":"White J. A. et al. Clonally expanded HIV-1 proviruses with 5\u2019-leader defects can give rise to nonsuppressible residual viremia. J. Clin. Invest. 133, e165245 (2023)","DOI":"10.1172\/JCI165245"},{"key":"62362_CR41","doi-asserted-by":"publisher","first-page":"e1006792","DOI":"10.1371\/journal.ppat.1006792","volume":"14","author":"KE Clarridge","year":"2018","unstructured":"Clarridge, K. E. et al. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 14, e1006792 (2018).","journal-title":"PLoS Pathog."},{"key":"62362_CR42","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1097\/QAD.0000000000001909","volume":"32","author":"E Papasavvas","year":"2018","unstructured":"Papasavvas, E. et al. Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV. AIDS 32, 1763\u20131772 (2018).","journal-title":"AIDS"},{"key":"62362_CR43","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1172\/JCI120194","volume":"128","author":"DB Salantes","year":"2018","unstructured":"Salantes, D. B. et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J. Clin. Invest. 128, 3102\u20133115 (2018).","journal-title":"J. Clin. Invest."},{"key":"62362_CR44","doi-asserted-by":"crossref","unstructured":"Strongin Z. et al. Effect of short-term antiretroviral therapy interruption on levels of integrated HIV DNA. J. Virol. 92, e00285-18 (2018).","DOI":"10.1128\/JVI.00285-18"},{"key":"62362_CR45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cell.2021.12.011","volume":"185","author":"KB Einkauf","year":"2022","unstructured":"Einkauf, K. B. et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell 185, 266\u2013282.e15 (2022).","journal-title":"Cell"},{"key":"62362_CR46","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1172\/JCI124291","volume":"129","author":"KB Einkauf","year":"2019","unstructured":"Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J. Clin. Invest 129, 988\u2013998 (2019).","journal-title":"J. Clin. Invest"},{"key":"62362_CR47","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1172\/JCI97555","volume":"128","author":"SH Huang","year":"2018","unstructured":"Huang, S. H. et al. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J. Clin. Invest 128, 876\u2013889 (2018).","journal-title":"J. Clin. Invest"},{"key":"62362_CR48","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.it.2022.06.002","volume":"43","author":"M Lichterfeld","year":"2022","unstructured":"Lichterfeld, M., Gao, C. & Yu, X. G. An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection. Trends Immunol. 43, 608\u2013616 (2022).","journal-title":"Trends Immunol."},{"key":"62362_CR49","first-page":"343","volume":"30","author":"JZ Li","year":"2016","unstructured":"Li, J. Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343\u2013353 (2016).","journal-title":"AIDS"},{"key":"62362_CR50","doi-asserted-by":"crossref","unstructured":"Sneller M. C., et al. A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci. Transl. Med. 9, eaan8848 (2017).","DOI":"10.1126\/scitranslmed.aan8848"},{"key":"62362_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24077-w","volume":"12","author":"LB Giron","year":"2021","unstructured":"Giron, L. B. et al. Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. Nat. Commun. 12, 3922 (2021).","journal-title":"Nat. Commun."},{"key":"62362_CR52","doi-asserted-by":"crossref","unstructured":"Bartsch Y. C. et al. Viral rebound kinetics correlate with distinct HIV antibody features. mBio. 12, e00170-21 (2021).","DOI":"10.1128\/mBio.00170-21"},{"key":"62362_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0392-7","volume":"15","author":"AE Baxter","year":"2018","unstructured":"Baxter, A. E., O\u2019Doherty, U. & Kaufmann, D. E. Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. Retrovirology 15, 18 (2018).","journal-title":"Retrovirology"},{"key":"62362_CR54","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41591-020-1022-1","volume":"26","author":"M Abdel-Mohsen","year":"2020","unstructured":"Abdel-Mohsen, M. et al. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat. Med. 26, 1339\u20131350 (2020).","journal-title":"Nat. Med."},{"key":"62362_CR55","doi-asserted-by":"crossref","unstructured":"Duette G. et al. The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. J. Clin. Invest. 132, e154422 (2022).","DOI":"10.1172\/JCI154422"},{"key":"62362_CR56","doi-asserted-by":"crossref","unstructured":"Stevenson E. M. et al. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight. 6, e142640 (2021).","DOI":"10.1172\/jci.insight.142640"},{"key":"62362_CR57","doi-asserted-by":"publisher","first-page":"9006","DOI":"10.1128\/JVI.79.14.9006-9018.2005","volume":"79","author":"RM Troyer","year":"2005","unstructured":"Troyer, R. M. et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J. Virol. 79, 9006\u20139018 (2005).","journal-title":"J. Virol."},{"key":"62362_CR58","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.1128\/JVI.79.14.9026-9037.2005","volume":"79","author":"B Joos","year":"2005","unstructured":"Joos, B. et al. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J. Virol. 79, 9026\u20139037 (2005).","journal-title":"J. Virol."},{"key":"62362_CR59","doi-asserted-by":"crossref","unstructured":"van Paassen P. M. et al. Soluble CD14 and IL-12p70 on early ART predict HIV load setpoint after treatment interruption. AIDS. 39, 812\u2013816 (2025).","DOI":"10.1097\/QAD.0000000000004159"},{"key":"62362_CR60","unstructured":"Booiman T. et al. High cellular monocyte activation in people living with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-matched controls is associated with greater inflammation in cerebrospinal fluid. Open Forum Infect. Dis. 4, ofx108 (2017)."},{"key":"62362_CR61","doi-asserted-by":"crossref","unstructured":"Booiman T. et al. Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. PloS ONE 12, e0183357 (2017).","DOI":"10.1371\/journal.pone.0183357"},{"key":"62362_CR62","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/infdis\/jiw146","volume":"214","author":"V Cobos Jim\u00e9nez","year":"2016","unstructured":"Cobos Jim\u00e9nez, V. et al. T-cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment. J. Infect. Dis. 214, 216\u2013225 (2016).","journal-title":"J. Infect. Dis."},{"key":"62362_CR63","doi-asserted-by":"publisher","first-page":"e89639","DOI":"10.1371\/journal.pone.0089639","volume":"9","author":"ML Grijsen","year":"2014","unstructured":"Grijsen, M. L. et al. Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment. PLoS ONE 9, e89639 (2014).","journal-title":"PLoS ONE"},{"key":"62362_CR64","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/QAD.0000000000000991","volume":"30","author":"N Pantazis","year":"2016","unstructured":"Pantazis, N. et al. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS 30, 879\u2013888 (2016).","journal-title":"AIDS"},{"key":"62362_CR65","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1128\/jcm.28.3.495-503.1990","volume":"28","author":"R Boom","year":"1990","unstructured":"Boom, R. et al. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28, 495\u2013503 (1990).","journal-title":"J. Clin. Microbiol."},{"key":"62362_CR66","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1128\/JCM.00055-08","volume":"46","author":"AO Pasternak","year":"2008","unstructured":"Pasternak, A. O. et al. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J. Clin. Microbiol. 46, 2206\u20132211 (2008).","journal-title":"J. Clin. Microbiol."},{"key":"62362_CR67","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/nprot.2008.108","volume":"3","author":"MS Malnati","year":"2008","unstructured":"Malnati, M. S. et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat. Protoc. 3, 1240\u20131248 (2008).","journal-title":"Nat. Protoc."},{"key":"62362_CR68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"62362_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100243","volume":"2","author":"CN Levy","year":"2021","unstructured":"Levy, C. N. et al. A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. Cell Rep. Med. 2, 100243 (2021).","journal-title":"Cell Rep. Med."},{"key":"62362_CR70","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1128\/JCM.43.4.1851-1857.2005","volume":"43","author":"W Luo","year":"2005","unstructured":"Luo, W., Yang, H., Rathbun, K., Pau, C. P. & Ou, C. Y. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J. Clin. Microbiol. 43, 1851\u20131857 (2005).","journal-title":"J. Clin. Microbiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62362-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62362-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62362-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:03:20Z","timestamp":1757322200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62362-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62362"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62362-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests. F.W.W. has served on the advisory board of ViiV Healthcare, paid to his institution. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6989"}}